Wednesday, November 15, 2006

NYT: FDA Panel on Sanofi-Aventis Drug Ketek

Article in the New York Times -- F.D.A. to Seek Advice of Expert Panel on Safety of Sanofi-Aventis Drug, by Reuters:

Food and Drug Administration officials said Tuesday they planned to ask outside advisers next month if the antibiotic Ketek made by Sanofi-Aventis should stay on the market after reports of liver failure in a dozen patients.

The antibiotic which was approved in 2004 is also the subject of a Senate Finance Committee investigation of the F.D.A.’s handling of the approval and of possibly faulty data.

“We will ask the committee if the overall risk/benefit profile supports continued marketing of Ketek for various indications,” an F.D.A. spokeswoman, Laura Alvey, said.

Here's a link to the Wall Street Journal article, Review of Sanofi Drug is Sought, by the Associated Press.

BGS

http://lawprofessors.typepad.com/mass_tort_litigation/2006/11/nyt_fda_panel_o.html

FDA | Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef00d835016a6369e2

Listed below are links to weblogs that reference NYT: FDA Panel on Sanofi-Aventis Drug Ketek:

Comments

Prof Erichson --

Had you for Civil Procedure at Seton Hall a number of years back and saw you commenting on a lot of pharmaceutical litigation -- Ketek is a very interesting drug -- as is hormone therapy which I saw they also asked you for comment on... that mistrial there was wild.

Posted by: Brian | Dec 5, 2006 8:30:18 PM

Brian -- Nice to hear from you, and I hope all's well. I haven't followed Ketek, but the Prempro/HRT litigation is at a really interesting stage, and I agree with you that the mistrial in Philadelphia was a strange twist. In my Complex Litigation class this semester, we'd been discussing the implications of the early Prempro trials as they developed in both the MDL and state court, and I recall my students' surprise at the news of the mistrial in the Jennie Nelson case.

Posted by: Howard Erichson | Dec 6, 2006 8:30:53 AM

Post a comment